Click image to view it in full size

Clinical genomics regained significance during the pandemic with the development of the mRNA COVID-19 vaccine, and several non-invasive at-home test kits-an unprecedented feat in recent times. Clinogenomics is a clinical outcome that uses genomic information and Computational methods, such as AI, ML, and deep learning (DL), to improve the understanding of hidden patterns in large, complex genomics datasets. Clinical research for identifying newer therapies and finding newer biomarkers for inherited and acquired diseases, can use this intelligence. AI is playing a significant role in clinogenomics. Artificial Intelligence (AI) is being used in the discovery of biomarkers for clinical diagnostics, consumer point-of-care-tests, and interpretative services.

The study offers insight into the industry environment of clinical genomics and AI, its value proposition, and applications and examines the participation of top technology companies in clinical genomics and the business opportunities created for all stakeholders. The study highlights ‘Use Cases and Impact Analyses’ of some of the most admired and innovative companies, such as Bionano Genomics, Deepcell, Fabric Genomics, Q-State Biosciences, Sophia Genetics, Illumina, Qiagen, and PierianDx.